Following a lackluster first quarter for small biotechs, the pharmaceutical industry is witnessing a surge in tuck-in deals. Ventyx, with upcoming Phase II Parkinson’s disease results, struck a deal with Sanofi granting the pharma right of first negotiation (ROFN) on an acquisition. This agreement, driven by a shared interest in novel central nervous system therapies, has sparked interest from other players like Lilly and AbbVie, who have a focus on immunology and CNS. While Sanofi leads negotiations, opportunities for competing bids remain open, signaling a dynamic landscape in small cap biotech acquisitions.
Read more from biospace.com
